Trial Profile
Atezolizumab in Combination With Gemcitabine and Cisplatin As First-Line Treatment in Metastatic Urothelial Cancer: A Multicenter Randomized Phase II Study of Two Alternative Dosing Schedules
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Jan 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cisplatin; Gemcitabine
- Indications Bladder cancer; Carcinoma; Pelvic cancer; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- 27 Dec 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Mar 2025.
- 27 Dec 2023 Planned End Date changed from 1 Mar 2024 to 1 Mar 2025.
- 23 Dec 2022 Planned End Date changed from 1 Mar 2023 to 1 Mar 2024.